VERWENDUNG EINES FIBROBLASTENWACHSTUMSFAKTOR- BINDEPROTEINS ZUR BEHANDLUNG UND DIAGNOSE VON DIABETISCHEN WUNDHEILUGNSSTÖRUNGEN

• Main Authors: GOPPELT, ANDREAS, BITTNER, MICHAELA
• Format: Patent
• Language: German
• Published: 15.10.2004
• Edition: 7
• Subjects: HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TESTING

Use of fibroblast growth factor binding protein (FGF-BP), nucleic acids encoding it, or their functional variants, antibodies against (FGF-BP) or their functional fragments, and/or cells that express (FGF-BP) or its variants, to prepare a composition for treatment, prevention and/or diagnosis of diabetes-associated wound-healing disorders, is new. Use of: (i) fibroblast growth factor binding protein (I: FGF-BP), with human sequence S1 of 234 amino acids or murine sequence S3 of 251 amino acids or their functional variants; (ii) nucleic acids (II) of 705 bp (S2) or 756 bp (S4), encoding (S1) and (S3), or their functional variants; (iii) antibodies against (I) or their functional fragments; and/or (iv) cells that express (I) or its variants, to prepare a composition for treatment, prevention and/or diagnosis of diabetes-associated wound-healing disorders. Independent claims are also included for the following: (1) use of (I), (II), Ab and (I)-expressing cells for identifying substances (A) that increase the function and/or expression of (I) and/or (II), suitable for treating or preventing skin disorders characterized by reduced levels of (I); and (2) use of the same materials as in (1) for preparing a reagent for diagnosis of wound-healing disorders characterized by reduced levels of (I).